BeiGene (BGNE) Should Be Up, Not Down - Maxim Group

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. RKLB
7. RXRX
8. NOW
9. CAT
10. FMC

Go back to BeiGene (BGNE) Should Be Up, Not Down - Maxim Group

Celgene Takeover Might Impact BeiGene's (BGNE) Tislelizumab Partnership - William Blair

January 3, 2019 2:17 PM EST

William Blair analyst Katherine Xu notes the acquisition of Celgene by Bristol-Myers might impact BeiGene's (NASDAQ: BGNE) Tislelizumab partnership.

BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumors in the United States, Europe, Japan and the rest of world outside Asia.

... More

BeiGene (BGNE) Sees Heavy Selling Pressure

January 3, 2019 9:57 AM EST

BeiGene (NASDAQ: BGNE) is under heavy pressure in early trade. Downside could be as a results of the Celgene/Bristol-Myers deal. Shares are down 17% on volume that is running 13x the norm.

... More